Hattie Hayes

Sir Jules Thorn Charitable Trust's investment will support a state-of-the-art, eye health research facility, opening in 2027

Jennifer I. Lim, MD, FARVO, FASRS sat down with Hattie Hayes of Ophthalmology Times Europe to discuss her findings, including exciting advancements in targeting Ang2 and VEGF from the Angiogenesis Exudation and Degeneration 2024 event.

Anat Loewenstein, MD, sat down with Hattie Hayes of Ophthalmology Times Europe to discuss the implication of longitudinal AI-based fluid quantification for at-home monitoring from the Angiogenesis Exudation and Degeneration 2024 event.

Carl D. Regillo, MD, FACS, FASRS, discussed recent data from the DAVIO 2 trial in his presentation at the virtual Angiogenesis, Exudation, and Degeneration 2024.

A review of Opthalmology Times Europe's most important content from throughout the year

Oxurion’s novel PKal Inhibitor, THR-149, did not meet its primary endpoint in the clinical trial.

Approach to lowering IOP reduces medication burden without risking graft rejection.

The improvement of accessibility and education could drive changes in outcomes.

Previously, the EMA had approved Eylea in a dosage of 2 mg. After considering the EMA’s recommendation, the European Commission will decide whether to issue final approval of the drug.

At this year's American Academy of Ophthalmology meeting, Mary Elizabeth Hartnett, MD, of the Byers Eye Institute at Stanford University presented on gender disparities in vision loss and blindness.

The ANTERION from Heidelberg Engineering offers a range of advanced diagnostic tools, including IOL power calculation, corneal topography, and tomography.

Novartis acquired Gyroscope Holdings Limited from Syncona in February 2022.

The non-profit will partner with the imaging company to prevent blindness and fund new retinoblastoma research.

The study met its primary efficacy endpoint for the neovascular age-related macular degeneration (nAMD) treatment.

The London-based company will use regenerative medicine to fight ocular disease.

The company seeks to replicate European success of the ELIOS procedure in the US market.